What conditions are associated with a positive Antinuclear Antibody (ANA) and a positive mitochondrial antibody blood test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Conditions Associated with Positive ANA and Positive Mitochondrial Antibody

The combination of positive ANA and positive mitochondrial antibody most commonly indicates autoimmune hepatitis-primary biliary cholangitis (AIH-PBC) overlap syndrome, though isolated mitochondrial antibody positivity can occur in 8-12% of autoimmune hepatitis patients without true overlap syndrome. 1

Primary Hepatobiliary Conditions

AIH-PBC Overlap Syndrome

  • AIH-PBC overlap syndrome is the most clinically significant diagnosis when both ANA and antimitochondrial antibody (AMA) are positive, occurring in 8-10% of AIH patients and 7.4-11.7% in Korean studies. 1
  • This overlap can be diagnosed simultaneously or sequentially—in one cohort, 7.8% were diagnosed with AIH and PBC simultaneously, 1.8% were diagnosed with AIH first, and 4.3% were diagnosed with PBC first. 1
  • Critical pitfall: AMA positivity alone should NOT be diagnostic for AIH-PBC overlap syndrome—8-12% of patients with AIH may be AMA-positive despite no histologic findings of bile duct damage or loss, and these patients respond well to glucocorticoid therapy alone. 1

AMA-Negative Primary Biliary Cholangitis

  • Conversely, antinuclear antibodies are frequently found in AMA-negative PBC patients, where ANA and antismooth muscle antibodies appear in the absence of histologic autoimmune hepatitis features. 2
  • AMA and ANA can fluctuate independently during the disease course—patients may transition between AMA-positive/ANA-negative, AMA-negative/ANA-negative, AMA-negative/ANA-positive, and AMA-positive/ANA-positive phases of the same disease. 3

Systemic Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)

  • SLE is the second most common concurrent autoimmune disease in AIH patients (2.2% prevalence), and AMA can be detected in patients with systemic lupus erythematosus as part of the broader autoimmune disease spectrum. 1, 4
  • Approximately 2.8-3% of patients with AIH are accompanied by SLE, and conversely, 2.7-4.7% of patients with SLE have concurrent AIH. 1

Sjögren's Syndrome

  • Sjögren's syndrome is associated with both positive ANA (typically nuclear speckled pattern with anti-SSA/Ro and anti-SSB/La antibodies) and can have concurrent AMA positivity. 5, 4
  • The association between AMA and Sjögren's syndrome is well established in the literature. 4

Systemic Sclerosis

  • Systemic sclerosis shows association with both ANA positivity (fine speckled pattern with anti-Topoisomerase-1) and can demonstrate concurrent AMA. 5, 4
  • This represents one of the established autoimmune disease associations with AMA beyond PBC. 4

Other Autoimmune Conditions Concurrent with AIH

The following conditions are associated with AIH (which commonly presents with positive ANA) and may theoretically co-occur with AMA positivity:

  • Autoimmune thyroid disease is the most common concurrent condition (10.5% of AIH cases), including Hashimoto's thyroiditis (10.2-14.1%) and Graves' disease (3-6%). 1
  • Rheumatoid arthritis occurs in 0.4% of AIH patients. 1
  • Mixed connective tissue disease, polymyositis, and other rheumatologic conditions are documented concurrent diagnoses. 1

Non-Autoimmune Liver Diseases

Viral Hepatitis and Other Liver Conditions

  • AMA can occur as an isolated serological finding in chronic hepatitis C (26% of cases), chronic hepatitis B (32%), non-alcoholic fatty liver disease (34%), and chronic alcohol-associated liver disease (21%). 6
  • Hepatitis C virus infection is associated with ANA positivity in approximately 26% of cases. 6
  • In unselected AMA-positive patient populations, only 38% have established PBC at a given time point, with medium and low anti-M2 titers present across various disease groups. 7

Important Clinical Considerations

Diagnostic Approach

  • The presence of both antibodies requires histologic evaluation to distinguish true AIH-PBC overlap syndrome from isolated AIH with incidental AMA positivity—this distinction is critical because treatment differs. 1
  • Very high and high anti-M2 values are present mainly in patients with PBC and some patients with other liver diseases, while medium and low values occur across different disease groups. 7

Monitoring and Prognosis

  • In the sub-cohort without established autoimmune disease, ANA positivity is associated with increased risk of Raynaud's syndrome and alveolar/perialveolar-related pneumopathies. 8
  • Approximately 10% of AMA-positive patients have a diagnosis of systemic autoimmune disease, and 3% have other organ-specific autoimmune diseases. 7

Key Pitfall to Avoid

  • Do not assume that positive AMA automatically means PBC or that positive ANA plus positive AMA automatically means overlap syndrome—clinical context, liver biochemistry patterns, and histology are essential for accurate diagnosis. 1, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antimitochondrial Antibodies: from Bench to Bedside.

Clinical reviews in allergy & immunology, 2022

Guideline

Nuclear Speckled ANA Pattern and Associated Autoimmune Diseases

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

ANA Positivity in Non-Rheumatologic Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical correlation of antimitochondrial antibodies.

European journal of medical research, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.